Drugs / tacedinaline
tacedinaline
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00004861 | Oct 1999 → Sep 2001 | malignant pancreatic neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00005624 | Aug 1997 → Feb 2003 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00005093 | Dec 1999 → May 2001 | lung cancer | Pfizer | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tacedinaline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004861 ↗ |
| Known as | Acetyldinaline | ChEMBL registry synonym — accepted as the source's own label CHEMBL235191 ↗ |
| Known as | CI-994 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005624 ↗ |
| Known as | GOE 5549 | ChEMBL registry synonym — accepted as the source's own label CHEMBL235191 ↗ |
| Known as | PD 123654 | ChEMBL registry synonym — accepted as the source's own label CHEMBL235191 ↗ |
| Known as | Tacedinalina | ChEMBL registry synonym — accepted as the source's own label CHEMBL235191 ↗ |
| Modality | Small molecule | — CHEMBL235191 ↗ |
| Route | Oral | “Patients receive CI-994 orally daily.” NCT00005624 ↗ |